# US 2016/0355576 A1 · Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355576 A1
- Document ID: US20160355576A1
- Status: Published application
- Kind: A1
- Application number: 15/106,176
- Filed: 2014-12-22
- Published: 2016-12-08
- Earliest claimed: 2013-12-20
- Assignees: Neurimmune Holding AG
- Applicants: Neurimmune Holding AG
- Inventors: Jan GRIMM; Aubin MICHALON
- Web page: https://patentgrep.com/patent/US20160355576A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 19/00: Drugs for skeletal disorders
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2800/28: Neurological disorders
- G01N 2800/7047: Fibrils-Filaments-Plaque formation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to anti-bodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.

## Claims

### Claim 1

A human-derived anti-transthyretin (TTR) antibody or an antigen-binding fragment thereof.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein at least the complementarity determining regions (CDRs) and/or variable region are encoded by a cDNA derived from an mRNA obtained from a human memory B cell which produced an anti-TTR antibody.

### Claim 3 (depends on 1, 2)

The antibody of claim 1 or 2, which is capable of binding mutated, misfolded, misassembled and/or aggregated TTR species and/or fragments thereof and does not substantially recognize physiological TTR species.

### Claim 4 (depends on 1, 2, 3)

The antibody of any one of claims 1 to 3, wherein the antibody is capable of binding
(i) a TTR epitope which comprises or consists of the amino acid sequence EEEFVEGIY (SEQ ID NO: 49), GELHGLTTEEE (SEQ ID NO: 50), or WEPFA (SEQ ID NO: 51), and/or
(ii) a non-linear, conformational epitope.

### Claim 5 (depends on 4)

The antibody of claim 4, wherein the antibody binds the TTR epitope (i) GELHGLTTEEE (SEQ ID NO: 50) but not a corresponding L55P mutant epitope or (ii) WEPFA (SEQ ID NO: 51) but not a corresponding E42G mutant.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The antibody of any one of claims 1 to 5 or a TTR binding molecule comprising in its variable region or binding domain
(a) at least one complementarity determining region (CDR) of the VH and/or VL variable region amino acid sequence depicted in any one of FIGS. 1A to 1T;
(b) an amino acid sequence of the VH and/or VL region as depicted in any one of FIGS. 1A to 1T;
(c) at least one CDR consisting of an amino acid sequence resulted from a partial alteration of any one of the amino acid sequences of (a); or
(d) a heavy chain and/or a light variable region comprising an amino acid sequence resulted from a partial alteration of the amino acid sequence of (b).

### Claim 7 (depends on 6)

The antibody of claim 6, wherein the antibody or antigen binding fragment thereof further comprises a polypeptide sequence which is heterologous to the VH and/or VL region or the least one CDR, preferably wherein polypeptide sequence comprises a constant domain

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the constant domain is a human constant domain, preferably of the IgG type, most preferably of the IgG1 class or isotype.

### Claim 9 (depends on 6)

An anti-TTR antibody or TTR-binding molecule which binds to the same epitope as the antibody of claim 6.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The antibody of any one of claims 5 to 9, which is a chimeric murine-human or a murinized antibody.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The antibody of any one of claims 1 to 10, which is an antibody fragment selected from the group consisting of a single chain Fv fragment (scFv), an F(ab′) fragment, an F(ab) fragment, and an F(ab′)2 fragment.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A polynucleotide encoding the antibody of any one of claims 1 to 11, preferably wherein the polynucleotide is a cDNA

### Claim 13 (depends on 12)

A vector comprising the polynucleotide of claim 12.

### Claim 14 (depends on 12, 13)

A host cell comprising the polynucleotide of claim 12 or a vector of claim 13.

### Claim 15 (depends on 12, 13, 14)

Use of the polynucleotide of claim 12, the vector of claim 13, or the host cell of claim 14 for the production of an anti-TTR antibody.

### Claim 16 (depends on 14)

A method for preparing an anti-TTR antibody or a biotechnological derivative thereof, said method comprising
(a) culturing the cell of claim 14; and
(b) isolating the antibody from the culture.

### Claim 17 (depends on 12, 16)

An antibody encoded by a polynucleotide of claim 12 or obtainable by the method of claim 16.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17)

The antibody of any one of claim 1 to 11 or 17, which
(i) comprises a detectable label, preferably wherein the detectable label is selected from the group consisting of an enzyme, a radioisotope, a fluorophore and a heavy metal; and/or
(ii) is attached to a drug.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17, 18)

A peptide having an epitope of TTR specifically recognized by an antibody of any one of claim 1 to 11, 17 or 18, preferably wherein the peptide comprises an amino acid sequence as defined in claim 4 or a modified sequence thereof in which one or more amino acids are substituted, deleted and/or added, wherein the peptide is recognized by the antibody of any one of claims 4 to 6, preferably wherein the peptide is an antigen.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19)

A composition comprising the antibody of any one of claim 1 to 11, 17 or 18, the polynucleotide of claim 12, the vector of claim 13, the cell of claim 14 or the peptide of claim 19, preferably wherein the composition
(i) is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier, preferably wherein the composition is a vaccine and/or comprises an additional agent useful for preventing or treating diseases associated with TTR amyloidosis; or
(ii) a diagnostic composition, preferably further comprising reagents conventionally used in immuno or nucleic acid based diagnostic methods.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20)

An anti-TTR antibody or a TTR-binding fragment of any one of claim 1 to 11, 17 or 18 having substantially the same binding specificities of any one thereof, the polynucleotide of claim 12, the vector of claim 13, the cell of claim 14, the peptide of claim 19 or the composition of claim 20 for use in the prophylactic or therapeutic treatment of a disease associated with TTR amyloidosis, preferably wherein the disease is selected from the group consisting of Familial Amyloid Polyneuropathy (FAP), Familial Amyloid Cardiomyopathy (FAC), Senile Systemic Amyloidosis (SSA), systemic familial amyloidosis, leptomeningeal/Central Nervous System (CNS) amyloidosis including Alzheimer disease, TTR-related ocular amyloidosis, TTR-related renal amyloidosis, TTR-related hyperthyroxinemia, TTR-related ligament amyloidosis including carpal tunnel syndrome, rotator cuff tears and lumbar spinal stenosis, and preeclampsia.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17, 18)

A TTR-binding molecule comprising at least one CDR of an antibody of any one of claim 1 to 11, 17 or 18 for use in in vivo detection or imaging of or targeting a therapeutic and/or diagnostic agent to TTR in the human or animal body, preferably wherein said in vivo imaging comprises scintigraphy, positron emission tomography (PET), single photon emission tomography (SPECT), near infrared (NIR), optical imaging or magnetic resonance imaging (MRI).

### Claim 23 (depends on 19)

An in vitro method for diagnosing a disorder associated with TTR amyloidosis, comprising steps of determining the presence of an antibody that binds to a peptide of claim 19 in a biological sample of said subject.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19)

A kit useful in the diagnosis or monitoring of a disorder associated with TTR amyloidosis, said kit comprising at least one antibody of any one of claim 1 to 11, 17 or 18 or a TTR binding molecule having substantially the same binding specificities of any one thereof, the polynucleotide of claim 12, the vector of claim 13 or the cell of claim 14 and/or the peptide of claim 19, optionally with reagents and/or instructions for use.

### Claim 25 (depends on 21)

A method of diagnosing a disease associated with TTR amyloidosis as defined in claim 21, monitoring the treatment of the disease with an anti-TTR antibody or determining the diagnostic or therapeutic utility of an anti-TTR antibody comprising assaying the level of misfolded and/or aggregated TTR in a sample of a body fluid from a subject following administration of an anti-TTR antibody to the subject, wherein the presence or elevated the level of misfolded and/or aggregated TTR in the sample of the subject compared to a control indicates a disease associated with TTR amyloidosis.

### Claim 26 (depends on 25)

The method of claim 25, wherein the level of misfolded and/or aggregated TTR in the sample is assayed by determining a complex formed between the anti-TTR antibody and the misfolded and/or aggregated TTR.

### Claim 27 (depends on 25, 26)

The method of claim 25 or 26, wherein the control is a sample obtained from the subject prior to administration of the anti-TTR antibody.

### Claim 28 (depends on 25, 26, 27)

The method of any one of claims 25 to 27, wherein the body fluid is blood and the sample is derived thereof and/or the control is a corresponding sample of a body fluid taken from the subject prior to administration of the anti-TTR antibody.

### Claim 29 (depends on 25, 26, 27, 28)

The method of any one of claims 25 to 28, wherein the subject is a non-human animal or a human

### Claim 30 (depends on 25, 26, 27, 28, 29, 30)

The method of any one of claims 25 to 30, wherein the sample from the subject is obtained at a specified time interval following administration.

### Claim 31 (depends on 30)

The method of claim 30, wherein the time interval is less than a week, preferably less than or equal to 48 hours.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17, 18, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 25 to 31, wherein the anti-TTR antibody is an anti-TTR antibody or antigen-binding fragment of any one of claim 1 to 11, 17 or 18.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 17, 18, 25, 26, 27, 28, 29, 30, 31, 32)

Use of an anti-TTR antibody in the method of any one of claims 25 to 32, preferably wherein the antibody is an anti-TTR antibody or antigen-binding fragment of any one of claim 1 to 11, 17 or 18.
